The global deep brain stimulation devices market size was valued at USD 1.0 billion in 2019 and is anticipated to expand at a CAGR of 9.6% over the forecast period. Increasing number of patients suffering from involuntary movements associated with dystonia, Parkinson’s disease, and multiple sclerosis and rising adoption of minimally invasive procedures are expected to drive the market growth. Increasing demand for minimally invasive techniques due to enhanced patient outcomes is also a high-impact rendering driver for the deep brain stimulation (DBS) devices market.
Deep brain stimulation (DBS) is a surgical procedure used to treat several disabling neurological diseases such as debilitating motor symptoms of Parkinson's Disease (PD), such as bradykinesia, rigidity, stiffness, essential tremor, psychiatric conditions (obsessive-compulsive disorder), and slowed movements. Deep brain stimulation therapy is generally recommended to the patients who do not respond to medicines for at least five years. In this treatment, electrodes are implanted in certain areas of affected brain, which produces electrical impulses that regulate abnormal impulses. Moreover, this treatment is approved by the U.S. Food and Drug Administration (FDA), for patients who cannot have epilepsy surgery, which separates or removes the part of the brain that causes seizures.
Potential benefits of deep brain stimulation devices, such as long-term efficacy and better management of postoperative outcomes, are expected to fuel the deep brain stimulation systems market growth. Furthermore, these advancements help clinical researchers in investigational efficacy studies for the inclusion of deep brain stimulation devices in the treatment of other neurological disorders. These key factors are anticipated to raise the demand for deep brain stimulation devices over the forecast period.
Advantages such as minimal pain, high cost-efficiency, safety, efficacy, and rapid recovery are also leading to increased demand. Factors responsible for replacing open/invasive surgeries with minimally invasive surgeries are lesser incision wounds, higher patient satisfaction, reduced hospital stay, postsurgical complications, and mortality rate. In addition, wound closure is simpler, and the recovery time is faster than that in traditional procedures. These benefits are cumulatively responsible for driving the DBS devices market growth.
The dual-channel deep brain stimulation device segment dominated the market in 2019 owing to higher adoption in surgical procedures. Dual deep brain stimulation devices are one of the safest and most effective devices used in surgical procedures. Thus, increasing number of surgical procedures for Parkinson's disease, prevalence of disabling neurological diseases, and an increasing number of hospitals using dual-channel deep brain stimulation devices systems are driving the market growth.
The single-channel deep brain stimulation device segment is expected to expand at the highest CAGR during the forecast period. Healthcare professionals believe that the single-channel offers more programming options to the neurologists, which led to increased preference for single-channel deep brain stimulation devices. According to the studies conducted by the Parkinson’s Foundation, geriatric population is more prone to neurological diseases such as PD. Increasing geriatric population, growing awareness about neurological diseases among patients, and preference by healthcare professionals are anticipated to trigger the segment growth.
Based on application, the Parkinson's disease segment dominated the market in 2019. In December 2017, Boston Scientific Corporation received approval for the Vercise deep brain stimulation device system from the U.S. FDA for the treatment of PD. According to the Parkinson’s Foundation, around 60,000 people in the U.S. are diagnosed with PD every year. Thus, the increasing number of U.S. FDA approvals for deep brain stimulation therapies and increasing prevalence of PD worldwide are driving the segment growth.
The Obsessive-Compulsive Disorder (OCD) segment is expected to register the highest CAGR during the forecast period. Increasing incidence of OCD and less effective therapeutics such as serotonin reuptake inhibitors are anticipated to drive the demand for treatment options with long-term effects. Deep brain stimulation therapy for the treatment of treatment-resistant and severe OCD is approved in the European Union, Australia, and the U.S. through Humanitarian Device Exemption (HDE) thus, fueling the market growth.
In the end-use segment, hospitals dominated the overall deep brain stimulation devices market growth in 2019, owing to the use of technologically advanced deep brain stimulation devices in operation theaters and intensive care units, increasing number of deep brain stimulation surgeries, rising prevalence of PD. Moreover, favorable reimbursement criteria is expected to further boost the growth of hospital end-use segment.
The ambulatory surgical centers (ASC) segment is expected to grow at the highest rate owing to lower cost as compared to hospitals, convenient access for patient care, reduced waiting time, and low infection rate as compared to neurology clinics and hospitals. Furthermore, according to a study conducted by Advancing Surgical Care, 92% of patients were satisfied with the medical care and service provided in the ASCs, thus, boosting the segment growth.
North America dominated the market owing to increase in FDA approvals for deep brain stimulation devices in clinical applications. For instance, in 2015, the U.S. FDA approved a deep brain stimulation device, Brio, for the treatment of Parkinson’s disease. Furthermore, an increasing number of patients diagnosed with PD has led to the growth of the overall market in the region.
Asia Pacific is expected to expand at the highest CAGR over the forecast period due to factors such as the rising prevalence of neurodegenerative disorders coupled with unmet demand for effective and long term solutions. Rising awareness about neurological disease treatment options and improvements in clinical development framework of emerging economies are expected to drive the market growth in this region.
Major players in the industry include Medtronic, Abbott, Aleva Neurotherapeutics SA, and Boston Scientific Corporation. These key market players are focusing on launching innovative medical devices, building growth strategies, and technological advancements to strengthen their position in the global market. For instance, in October 2019, Medtronic launched its Activa neurostimulators for the treatment of patients suffering from essential tremor and associated symptoms. These advancements are anticipated to boost the market growth over the forecast period.
Base year for estimation
Actual estimates/ Historical data
2016 - 2018
2020 - 2027
Revenue in USD Million and CAGR from 2020 to 2027
North America, Europe, Asia Pacific, Latin America, and MEA
U.S., Canada, U.K., Germany, France, Italy, Spain, Russia, Netherlands, Switzerland, Sweden, Ireland, Poland, Japan, China, India, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Brazil, Mexico, Colombia, Argentina, Chile, Venezuela, South Africa, Saudi Arabia, UAE, Turkey, Iran
Revenue, competitive landscape, growth factors, and trends
15% free customization scope (equivalent to 5 analysts working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global deep brain stimulation devices market report on the basis of product, application, end use, and region:
Product Outlook (Revenue USD Million, 2016 - 2027)
Application Outlook (Revenue USD Million, 2016 - 2027)
Obsessive-Compulsive Disorder (OCD)
End-use Outlook (Revenue USD Million, 2016 - 2027)
Ambulatory Surgical Centers
Regional Outlook (Revenue, USD Million, 2016 - 2027)
Middle East and Africa (MEA)
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.